Supernus Pharmaceuticals/$SUPN
1D1W1MYTD1Y5YMAX
Capital at risk
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
- Ticker
- $SUPN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 778
- Headquarters
- Rockville, United States
- Website
- www.supernus.com
SUPN Metrics
BasicAdvanced
$2.4B
-
-$1.91
0.56
-
Price and volume
Market cap
$2.4B
Beta
0.56
52-week high
$59.68
52-week low
$40.51
Average daily volume
657K
Financial strength
Current ratio
2.083
Quick ratio
1.68
Long term debt to equity
0.029
Total debt to equity
0.029
Interest coverage (TTM)
1.44%
Profitability
EBITDA (TTM)
110.432
Gross margin (TTM)
72.89%
Net profit margin (TTM)
-13.23%
Operating margin (TTM)
1.05%
Effective tax rate (TTM)
11.00%
Revenue per employee (TTM)
$1,070,000
Management effectiveness
Return on assets (TTM)
0.39%
Return on equity (TTM)
-10.49%
Valuation
Price to revenue (TTM)
2.861
Price to book
2.33
Price to tangible book (TTM)
5.44
Price to free cash flow (TTM)
126.447
Free cash flow yield (TTM)
0.79%
Free cash flow per share (TTM)
0.327
Growth
Revenue change (TTM)
24.85%
Earnings per share change (TTM)
-267.36%
3-year revenue growth (CAGR)
9.41%
10-year revenue growth (CAGR)
16.59%
3-year earnings per share growth (CAGR)
36.02%
10-year earnings per share growth (CAGR)
14.82%
What the Analysts think about SUPN
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
Analyst projections of the future price of Supernus Pharmaceuticals stock.
SUPN Financial Performance
Revenues and expenses
SUPN Earnings Performance
Company profitability
Upcoming events
No upcoming events
SUPN News
AllArticlesVideos
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 weeks ago
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Business Wire1 month ago
Supernus Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat1 month ago
Funds containing SUPN
AllUSDEURGBP
Fund name | Fund size | $SUPN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.25% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.25% |
iShares Healthcare Innovation£DRDR | £1B | 0.25% |
iShares Ageing Population€AGED | €822M | 0.20% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.